Sanofi will take the rights to Arrowhead Pharmaceuticals’ late-stage lipid-lowering asset plozasiran in China for $130 million upfront and up to $265 million in biobucks.
The deal was struck through Visirna Therapeutics, a subsidiary Arrowhead ...
↧